AAOS2018: TXA effective in operative management for high-energy pelvic and femoral fractures .
Use of Tranexamic Acid in High-Energy Fractures of the Pelvis and Femur
84 patients with a high-energy fracture of the pelvis or femur and scheduled for open reduction and internal fixation were randomized to perioperative intravenous tranexamic acid (TXA) or no tranexamic acid (control). Patients were assessed for calculated total blood loss, transfusion rate, number of units transfused, postoperative drop in hematocrit, and incidence of venous thromboembolic complications. Despite a significantly smaller drop in hematocrit in the TXA group, no significant differences between groups were observed in calculated total blood loss and transfusion rate. However, there were trends towards improved blood conservation with the use of TXA in these patient populations.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
